keyword
https://read.qxmd.com/read/38650797/delayed-serotonin-syndrome-and-non-cardiogenic-pulmonary-edema-following-bupropion-overdose-in-a-seven-year-old-female-a-case-report-and-review-of-literature
#1
Madison P Craft, Kaitlyn Burdsall, Hanna S Sahhar
Bupropion is an atypical antidepressant prescribed for depression and attention-deficit/hyperactivity disorder and to aid in smoking cessation. Bupropion overdose management is largely aimed toward common sequelae, including seizures, tachycardia, and QTc prolongation. In this case report, we identify a rare event of pediatric bupropion overdose with aforementioned common sequela and atypical features, including a delayed presentation of serotonin syndrome and non-cardiogenic pulmonary edema. This case follows a seven-year-old Caucasian female with autism spectrum disorder (ASD) who presented in status epilepticus following an accidental bupropion overdose and required multiple anti-seizure medications, endotracheal intubation, and admission to the pediatric intensive care unit (PICU)...
March 2024: Curēus
https://read.qxmd.com/read/38648694/visual-hallucinations-originating-in-the-retinofugal-pathway-under-clinical-and-psychedelic-conditions
#2
REVIEW
Zeus Tipado, Kim P C Kuypers, Bettina Sorger, Johannes G Ramaekers
Psychedelics like LSD (Lysergic acid diethylamide) and psilocybin are known to modulate perceptual modalities due to the activation of mostly serotonin receptors in specific cortical (e.g., visual cortex) and subcortical (e.g., thalamus) regions of the brain. In the visual domain, these psychedelic modulations often result in peculiar disturbances of viewed objects and light and sometimes even in hallucinations of non-existent environments, objects, and creatures. Although the underlying processes are poorly understood, research conducted over the past twenty years on the subjective experience of psychedelics details theories that attempt to explain these perceptual alterations due to a disruption of communication between cortical and subcortical regions...
April 21, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38641607/can-essential-fatty-acids-efas-prevent-and-ameliorate-post-covid-19-long-haul-manifestations
#3
REVIEW
Undurti N Das
It is hypothesized that COVID-19, post-COVID and post-mRNA COVID-19 (and other related) vaccine manifestations including "long haul syndrome" are due to deficiency of essential fatty acids (EFAs) and dysregulation of their metabolism. This proposal is based on the observation that EFAs and their metabolites can modulate the swift immunostimulatory response of SARS-CoV-2 and similar enveloped viruses, suppress inappropriate cytokine release, possess cytoprotective action, modulate serotonin and bradykinin production and other neurotransmitters, inhibit NF-kB activation, regulate cGAS-STING pathway, modulate gut microbiota, inhibit platelet activation, regulate macrophage and leukocyte function, enhance wound healing and facilitate tissue regeneration and restore homeostasis...
April 19, 2024: Lipids in Health and Disease
https://read.qxmd.com/read/38641430/take-it-easy-serotonin-syndrome-precipitated-by-the-rapid-titration-of-sertraline-and-trazodone-in-the-setting-of-risperidone-use
#4
JOURNAL ARTICLE
Julie Martino, Zane Elfessi, Katarzyna Szaflarska, Melody Suh, Katerina Antonishina
Serotonin syndrome is a potentially life-threatening condition caused by a toxic excess of serotonin leading to overstimulation of the nervous system. Because it is a diagnosis of exclusion, it can be underrecognized, making the true incidence unknown. The classic triad of serotonin syndrome includes neuromuscular excitation, autonomic instability and altered mental status. If left unrecognized and untreated, patients are at a high risk of mortality. The most common class of medication that carries an increased risk of serotonin syndrome, when used in combination, is selective serotonin reuptake inhibitors (SSRIs); however, medications that increase serotonin production, increase serotonin release, inhibit serotonin metabolism and stimulate serotonin receptors can increase the possibility of serotonin syndrome...
April 19, 2024: Journal of Pharmacy Practice
https://read.qxmd.com/read/38633030/serious-adverse-drug-events-associated-with-psychotropic-treatment-of-bipolar-or-schizoaffective-disorder-a-17-year-follow-up-on-the-lisie-retrospective-cohort-study
#5
JOURNAL ARTICLE
Petra Truedson, Michael Ott, Lisa Wahlström, Robert Lundqvist, Martin Maripuu, Krister Lindmark, Ingrid Lieber, Ursula Werneke
INTRODUCTION: Mood stabilisers and other psychotropic drugs can lead to serious adverse drug events (ADEs). However, the incidence remains unknown. We aimed to (a) determine the incidence of serious ADEs in patients with bipolar or schizoaffective disorders, (b) explore the role of lithium exposure, and (c) describe the aetiology. METHODS: This study is part of the LiSIE (Lithium-Study into Effects and Side Effects) retrospective cohort study. Between 2001 and 2017, patients in the Swedish region of Norrbotten, with a diagnosis of bipolar or schizoaffective disorder, were screened for serious ADEs to psychotropic drugs, having resulted in critical, post-anaesthesia, or intensive care...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38627042/serotonin-syndrome-presenting-as-acute-dizziness-with-supine-hypertension-and-orthostatic-hypotension
#6
JOURNAL ARTICLE
Sanjay Prakash, Ravisha Gupta, Maitree M Raval, Charu Tibrewal
Serotonin syndrome (SS) is a drug-induced clinical syndrome characterised by a combination of cognitive, neuromuscular and autonomic dysfunctions. The symptoms may include mild non-specific symptoms such as tremors and diarrhoea to coma and sudden death. Herein, we describe a case of SS in which acute dizziness was associated with supine hypertension and orthostatic hypotension. A man in his mid-30s had a 10-month history of anxiety, depression and chronic tension-type headache. He had been on amitriptyline (25 mg daily) and sertraline (50 mg daily)...
April 16, 2024: BMJ Case Reports
https://read.qxmd.com/read/38622839/amitriptyline-at-low-dose-for-burning-mouth-syndrome
#7
JOURNAL ARTICLE
Takahiko Nagamine
No abstract text is available yet for this article.
April 15, 2024: Oral Diseases
https://read.qxmd.com/read/38616061/concomitant-treatment-with-safinamide-and-antidepressant-drugs-safety-data-from-real-clinical-practice
#8
JOURNAL ARTICLE
P Pérez-Torre, J L López-Sendón, V Mañanes Barral, I Parees, S Fanjul-Arbós, E Monreal, A Alonso-Canovas, J C Martínez Castrillo
BACKGROUND AND PURPOSE: The aim of this study was to assess the possible pharmacological interactions between safinamide and antidepressants, and in particular the appearance of serotonin syndrome with data from real life. METHODS: We conducted a retrospective observational study of patients with Parkinson's disease from our Movement Disorders Unit, who were under treatment with any antidepressant drug and safinamide. Specifically, symptoms suggestive of serotonin syndrome were screened for...
May 2024: Neurología
https://read.qxmd.com/read/38609530/rebound-activation-of-5-ht-neurons-following-ssri-discontinuation
#9
JOURNAL ARTICLE
Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Sharp
Cessation of therapy with a selective serotonin (5-HT) reuptake inhibitor (SSRI) is often associated with an early onset and disabling discontinuation syndrome, the mechanism of which is surprisingly little investigated. Here we determined the effect on 5-HT neurochemistry of discontinuation from the SSRI paroxetine. Paroxetine was administered repeatedly to mice (once daily, 12 days versus saline controls) and then either continued or discontinued for up to 5 days. Whereas brain tissue levels of 5-HT and/or its metabolite 5-HIAA tended to decrease during continuous paroxetine, levels increased above controls after discontinuation, notably in hippocampus...
April 12, 2024: Neuropsychopharmacology
https://read.qxmd.com/read/38608060/serotonin-syndrome-treated-with-cyproheptadine-using-npi-from-a-digital-pupillometer-as-a-therapeutic-indicator-a-case-report
#10
JOURNAL ARTICLE
Kazuki Sugaya, Tomotaka Misawa, Makoto Onodera, Ken Iseki
RATIONALE: Serotonin syndrome is a potentially life-threatening condition resulting from the use of antidepressants, their interactions with other serotonergic medications, or poisoning. It presents with a triad of psychiatric, dysautonomic, and neurological symptoms and is sometimes fatal. While cyproheptadine is a specific treatment option, the optimal duration of its administration remains unclear. The purpose of this report is to quantitatively assess the endpoints of serotonin syndrome treatment...
April 12, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38596485/serotonin-receptor-2b-induces-visceral-hyperalgesia-in-rat-model-and-patients-with-diarrhea-predominant-irritable-bowel-syndrome
#11
JOURNAL ARTICLE
Zheng-Yang Li, Yu-Qing Mao, Qian Hua, Yong-Hong Sun, Hai-Yan Wang, Xuan-Guang Ye, Jing-Xian Hu, Ya-Jie Wang, Miao Jiang
BACKGROUND: Serotonin receptor 2B (5-HT2B receptor) plays a critical role in many chronic pain conditions. The possible involvement of the 5-HT2B receptor in the altered gut sensation of irritable bowel syndrome with diarrhea (IBS-D) was investigated in the present study. AIM: To investigate the possible involvement of 5-HT2B receptor in the altered gut sensation in rat model and patients with IBS-D. METHODS: Rectosigmoid biopsies were collected from 18 patients with IBS-D and 10 patients with irritable bowel syndrome with constipation who fulfilled the Rome IV criteria and 15 healthy controls...
March 14, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38595149/central-neuromodulators-in-irritable-bowel-syndrome-why-how-and-when
#12
JOURNAL ARTICLE
Ignacio Hanna-Jairala, Douglas A Drossman
Irritable bowel syndrome are responsive to treatments using central neuromodulators. Central neuromodulators work by enhancing the synaptic transmission of 5-hydroxytryptamine, noradrenalin and dopamine, achieving a slower regulation or desensitization of their postsynaptic receptors. Central neuromodulators act on receptors along the brain-gut axis, so they are useful in treating psychiatric comorbidities, modifying gut motility, improving central downregulation of visceral signals and enhancing neurogenesis in patients with IBS...
April 9, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38593237/enhancing-the-action-of-serotonin-by-three-different-mechanisms-prevents-spontaneous-seizure-induced-mortality-in-dravet-mice
#13
JOURNAL ARTICLE
Jialing Guo, Daniel Min, Emory K Farrell, Yupeng Zhou, Carl L Faingold, Joseph F Cotten, Hua-Jun Feng
OBJECTIVE: Sudden unexpected death in epilepsy (SUDEP) is an underestimated complication of epilepsy. Previous studies have demonstrated that enhancement of serotonergic neurotransmission suppresses seizure-induced sudden death in evoked seizure models. However, it is unclear whether elevated serotonin (5-HT) function will prevent spontaneous seizure-induced mortality (SSIM), which is characteristic of human SUDEP. We examined the effects of 5-HT-enhancing agents that act by three different pharmacological mechanisms on SSIM in Dravet mice, which exhibit a high incidence of SUDEP, modeling human Dravet syndrome...
April 9, 2024: Epilepsia
https://read.qxmd.com/read/38590512/-s-s-adenosylmethionine-in-the-treatment-of-pre-menstrual-disorders-in-adult-women-a-protocol-for-an-open-label-pilot-study
#14
JOURNAL ARTICLE
Brendan Stevenson, Emorfia Gavrilidis, Yasmin Malik, Jayashri Kulkarni
Pre-menstrual disorders, including pre-menstrual syndrome and pre-menstrual dysphoric disorder, are highly prevalent disorders in women of reproductive age. Pre-menstrual disorders are associated with debilitating symptoms that onset in the days prior to menses. A complex interplay between hormonal fluctuations, cellular sensitivity, and psychosocial stressors likely underly the pathophysiology of pre-menstrual disorders. Current treatment options include selective serotonin reuptake inhibitors, hormonal therapies, and psychosocial support...
June 2024: Contemporary Clinical Trials Communications
https://read.qxmd.com/read/38586704/linezolid-toxicity-a-clinical-case-report
#15
Ângela Ferreira, Patrícia Sobrosa, Miguel Costa, Irene Miranda, Diana Guerra
Linezolid plays a clinically important role; however, it is responsible for severe pharmacological interactions and side effects, such as myelosuppression, serotonin syndrome, and lactic acidosis. We report a case of an 80-year-old man treated with venlafaxine for depression. He was admitted with a right femur fracture and submitted to surgical intervention, complicated by local infection. In collected pus was identified multiple microorganisms including Enterococcus faecium resistant to vancomycin. The therapeutic was adjusted to linezolid...
March 2024: Curēus
https://read.qxmd.com/read/38576478/low-tgf-%C3%AE-1-plasma-levels-are-associated-with-cognitive-decline-in-down-syndrome
#16
JOURNAL ARTICLE
Margherita Grasso, Annamaria Fidilio, Francesca L'Episcopo, Marilena Recupero, Concetta Barone, Maria Giulia Bacalini, Cristina Benatti, Maria Concetta Giambirtone, Giuseppe Caruso, Donatella Greco, Santo Di Nuovo, Corrado Romano, Raffaele Ferri, Serafino Buono, A Claudio Cuello, Johanna M C Blom, Fabio Tascedda, Pier Vincenzo Piazza, Rafael De La Torre, Filippo Caraci
Almost all individuals with Down's syndrome (DS) show the characteristic neuropathological features of Alzheimer's disease (AD) by the age of 40, yet not every individual with DS experiences symptoms of AD later in life. Similar to neurotypical developing subjects, AD in people with DS lasts for a long preclinical phase in which biomarkers follow a predictable order of changes. Hence, a prolonged asymptomatic period precedes the onset of dementia, underscoring the importance of identifying new biomarkers for the early detection and monitoring of cognitive decline in individuals with DS...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38571846/trends-and-prevalence-of-psychotropic-medication-use-in-children-and-adolescents-in-the-period-between-2013-and-2023-a-systematic-review
#17
REVIEW
Yasir Altuwairqi
Mental health problems among children and adolescents are a significant global public health concern, with a prevalence of approximately 10-20%. Psychotropic medications, including stimulants, antipsychotics, antidepressants, and mood stabilizers, have been proven effective in treating various psychiatric disorders among children and adolescents. Despite the common use of these medications, they have various side effects and complications. This systematic review aimed to assess the trends and prevalence of psychotropic medication use among children and adolescents from 2013 to 2023...
March 2024: Curēus
https://read.qxmd.com/read/38569181/serotonin-syndrome-and-dextromethorphan-toxicity-caused-by-drug-drug-interaction-between-fluoxetine-and-bupropion-dextromethorphan-a-case-report
#18
JOURNAL ARTICLE
Michelle Anjali Singh, Devon Johnson
No abstract text is available yet for this article.
April 3, 2024: Journal of Clinical Psychiatry
https://read.qxmd.com/read/38562274/biochemical-abnormalities-associated-with-sudden-infant-death-syndrome-a-case-report
#19
Roshani S Ganjare, Anjali A Vagga, Archana Dhok, Ashish Anjankar, Roshan K Jha, Pratiksha S Batulwar
Sudden infant death is a complex event characterized by biochemical features that are difficult to understand in general settings. Herein, we present a case report of a three-month-old infant who succumbed to sudden infant death syndrome (SIDS), focusing on the biochemical abnormalities identified through post-mortem analysis. The infant, previously healthy and meeting developmental milestones, was found lifeless in the crib during sleep. An autopsy revealed no anatomical abnormalities or signs of external trauma, consistent with SIDS diagnosis...
February 2024: Curēus
https://read.qxmd.com/read/38558725/peripheral-nerve-stimulation-for-a-refractory-case-of-postherpetic-neuralgia-in-the-upper-limb-a-case-report
#20
Arun Kalava, Simeon V Mihaylov, Harriet Kaye Austin, Saru Acharya
Postherpetic neuralgia (PHN) is a chronic neuropathic pain syndrome that is a direct consequence of the reactivation of varicella zoster virus (VZV). It manifests as neuropathic pain, which is pain that occurs because of dysfunction or damage of the nerves that carry sensations to the brain, and this typically persists for months to years after herpes zoster. Current conservative management for PHN includes a combination of topical agents (i.e., lidocaine and capsaicin) and systemic therapy (i.e., serotonin and norepinephrine reuptake inhibitors (SNRIs), gabapentin, pregabalin, and opioids)...
February 2024: Curēus
keyword
keyword
676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.